Design and evaluation of oral formulation for apixaban

Non-valvular atrial fibrillation (NVAF) is a common form of cardiac arrhythmia that affects 1–1.5% adults and roughly 10% elderly with dysphagia. Apixaban an anticoagulant referred to as factor Xa inhibitor, which has been shown reduce the risk stroke systemic embolism in cases NVAF. Our objective current study was formulate orally disintegrating film facilitate administration apixaban patients who have difficulty swallowing. Researchers used wide variety cellulose-based or non-cellulose-based polymers combinations achieve specific characteristics related formation, disintegration performance, drug content, vitro release, stability. One two formulations this specify bioequivalence criteria met respect Cmax reference (ELIQUIS®) terms pharmacokinetic profile. Further research will be required assess applicability orodispersible films created using colloidal high low molecular weights other drugs poor solubility water.